Janus Henderson Group PLC Biocryst Pharmaceuticals Inc Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 79,332 shares of BCRX stock, worth $600,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,332

Previous 79,332 -0.0%

Holding current value

$600,543

Previous $490,000 22.86%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $4,348 - $7,149	-1,053 Reduced 1.31%	79,332 $490,000
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $479 - $749	98 Added 0.12%	80,385 $408,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $776 - $1,056	-156 Reduced 0.19%	80,287 $480,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $46 - $55	7 Added 0.01%	80,443 $569,000
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $598 - $757	-86 Reduced 0.11%	80,436 $566,000
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $15.6 Million - $23.3 Million	-1,969,504 Reduced 96.07%	80,522 $671,000
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $21.1 Million - $28.6 Million	2,014,048 Added 5598.0%	2,050,026 $23.5 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $830 - $1,140	77 Added 0.21%	35,978 $453,000
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $236 - $536	-30 Reduced 0.08%	35,901 $380,000
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $104 - $177	9 Added 0.03%	35,931 $584,000
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $202,000 - $279,331	18,068 Added 101.2%	35,922 $498,000
Q3 2021 Nov 16, 2021	BUY	$14.21 - $17.65 $253,705 - $315,123	17,854 New	17,854 $257,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $9.27 Million - $27.4 Million	-4,877,731 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$1.6 - $4.11 $7.25 Million - $18.6 Million	-4,530,750 Reduced 48.16%	4,877,731 $9.76 Million
Q4 2019 Feb 18, 2020	SELL	$1.59 - $3.45 $178,211 - $386,686	-112,083 Reduced 1.18%	9,408,481 $32.5 Million
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $189,450 - $282,659	-75,780 Reduced 0.79%	9,520,564 $27.3 Million
Q2 2019 Jul 31, 2019	SELL	$2.91 - $9.15 $7.74 Million - $24.3 Million	-2,661,098 Reduced 21.71%	9,596,344 $36.4 Million
Q1 2019 Apr 30, 2019	SELL	$7.38 - $9.72 $332,933 - $438,498	-45,113 Reduced 0.37%	12,257,442 $99.8 Million
Q4 2018 Feb 06, 2019	BUY	$6.51 - $9.6 $341,084 - $502,982	52,394 Added 0.43%	12,302,555 $99.3 Million
Q3 2018 Nov 09, 2018	BUY	$5.52 - $7.99 $6.37 Million - $9.22 Million	1,153,978 Added 10.4%	12,250,161 $93.5 Million
Q2 2018 Aug 10, 2018	BUY	$4.6 - $6.52 $15.8 Million - $22.4 Million	3,441,498 Added 44.96%	11,096,183 $63.6 Million
Q1 2018 May 14, 2018	BUY	$4.35 - $5.82 $3.98 Million - $5.33 Million	915,419 Added 13.58%	7,654,685 $36.5 Million
Q4 2017 Feb 09, 2018	BUY	$4.16 - $5.33 $9.17 Million - $11.8 Million	2,204,539 Added 48.61%	6,739,266 $33.1 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $18.6 Million - $27.1 Million	4,534,727	4,534,727 $0

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Biocryst Pharmaceuticals Inc Transaction History